West Pharmaceutical Services (WST)
Supplies injectable-drug containment, delivery systems, and contract device manufacturing.
Something off on this page? Send us feedback.
West Pharmaceutical makes the unglamorous parts that touch injectable medicines — rubber stoppers, seals and syringe plungers — plus the devices and assembly work around them. It sells no medicines of its own. Once a drug company writes a West part into its regulatory filing, switching suppliers means re-doing the paperwork, so orders keep coming. The company is now steadily moving customers from plain parts to washed, coated, camera-checked ones at higher prices.
Item facts: FY2025 · year ended December 31, 2025, from filings, earnings calls and company pages.
Judgment weights, not filed revenue
The band summarizes business focus and direction. ~ marks estimates.
8 in detail · 14 more below
High-Value Components (NovaPure, Westar)
Washed, coated and camera-checked stoppers and plungers for biologic medicines — the single biggest engine, at 49% of sales in the latest quarter and guided to grow in the high teens this year.
Competes with OmniFlex stoppers · NeoFlex plungers (Datwyler) · PremiumCoat coated stoppers and plungers (Aptar)
In plain English
Think of the rubber stopper in a drug vial. The plain version just seals the bottle. This is the same part, washed, coated with a slippery film, checked by cameras and shipped with a paper trail — because a modern biologic medicine reacts with anything less.
Drug companies pay notably more per part for that, and they keep paying: the exact stopper is written into the medicine's regulatory filing, so swapping it means re-doing safety work with the regulator. West says it is on more than nine in ten new biologic and copycat-biologic approvals. The buyers are few — ten customers were just under half of 2025 sales, and one customer West does not name was about a sixth on its own.
GLP-1 component and assembly program
Seals for weight-loss and diabetes injections, plus the pens West snaps together — management sizes the whole thing near 17% of sales. Whether the new pills add patients or replace shots is the thing to watch.
Competes with Coated seals for pens and vials (Datwyler) · Auto-injector pen assembly (Phillips-Medisize) · Device moulding and assembly (SMC Ltd.)
In plain English
The weight-loss and diabetes injections that have become the fastest-growing part of West's mix reach patients as a vial, a cartridge or a pre-filled pen. Every one of those needs a rubber seal West makes, and some of the pens are assembled by West too.
So the same wave pays twice: once for the parts, once for the assembly labour. Management says most of the volume sits with the two biggest makers of these drugs, and declines to name them. Its own read is that the new swallowable versions bring in fresh patients rather than replace injections — if that read is wrong, this is the line that feels it first.
Annex 1 upgrade program
Europe's rewritten hygiene rules push drug companies to re-qualify medicines already on sale onto upgraded parts — about two points of 2025 growth. Under 15% of roughly six billion West parts on marketed drugs has converted so far.
Competes with OmniFlex and NeoFlex conversions (Datwyler) · PremiumCoat conversions (Aptar)
In plain English
European rules for making injectable medicines were rewritten, and the new version asks manufacturers to prove they keep particles and germs out at every step. One response is to buy parts that arrive already washed, coated and camera-checked.
That turns a rulebook into a sales pipeline. Each switch is its own small project — West has counted hundreds running at once, over seven hundred started in total — and when one lands, a customer who was buying the cheap part starts buying the expensive one instead. No new factory, no new customer: the same parts, at a better price.
Daikyo Seiko alliance
West owns 49% of Daikyo Seiko in Japan and licenses its coating film and clear syringe plastic. The agreements were renewed in July 2026 for ten years, taking renewal worry off the table until 2036.
Competes with In-house fluoropolymer spray coating (Datwyler) · In-house ETFE film coating (Aptar)
In plain English
What makes West's premium stopper premium is partly a paper-thin slippery film called FluroTec — and West does not own it. It licenses that film, plus a clear plastic used for syringes and containers, from Daikyo Seiko, a Japanese partner of more than fifty years that West owns just under half of.
The arrangement runs both ways: West sells Daikyo's products everywhere outside Japan, Daikyo sells West's inside Japan, and the stake means a share of Daikyo's economics comes back to West. Its two main rivals coat parts in their own plants. West rents the recipe instead — and has just re-signed the lease for a decade.
Standard Products
Plain uncoated stoppers and seals, roughly a fifth of sales and growing 0–1% on purpose. Its job is to be the pool that upgrades come from; the risk is price competition at the cheap end, not lost volume.
Competes with Uncoated bromobutyl stoppers (Datwyler) · Base bromobutyl formulations (Aptar)
In plain English
The unglamorous bottom rung. A plain rubber stopper, moulded and shipped — no coating, no washing service, no camera check, and a price to match. Generic and simple medicines do not need more than that.
Growth here is close to nothing, and West is relaxed about it, because these are exactly the customers it wants to move up a rung. Every conversion takes a dollar out of this line and puts a bigger one into the coated line, so flat is what winning looks like here. What would actually hurt is rivals undercutting on price at the cheap end.
West Vantage
The contract arm: West moulds and assembles devices other companies designed, $582.0M in 2025. Management calls the third quarter of 2026 its low point as a glucose-monitor contract exits and the May break-in still echoes.
Competes with Phillips-Medisize contract assembly (Molex) · Regional moulding and assembly (SMC Ltd.) · Packaging and assembly services (PCI Pharma)
In plain English
Other companies bring the blueprint; West runs the factory. Clean-room moulding, welding and automated assembly of things somebody else designed and sells — injector pens, surgical, eye-care and diagnostic items, even consumer products.
Customers pay per part built, so the money follows how full the lines are. Two things emptied them this year: a glucose-monitor programme West decided not to renew is rolling off, and the May 2026 computer break-in that encrypted systems pushed work into later months. New drug-handling work at the expanded Dublin plant, around $20M this year, is meant to fill the space.
Delivery Devices (SelfDose, Crystal Zenith)
West's own injectors and clear-plastic syringe systems, about 14% of sales. The line grew 29% in the latest quarter, flattered by orders pulled forward before the SmartDose handover to AbbVie removed roughly $110M of annual sales.
Competes with Nexa and Alba syringe systems (Stevanato) · PremiumCoat plungers for prefilled syringes (Aptar)
In plain English
Beyond the stoppers, West sells finished hardware: a small injector the patient presses themselves, and syringes and containers made from a clear plastic rather than glass, licensed from its Japanese partner.
Drug companies buy these when they want the dose given by the patient rather than by a clinician, and they buy by the unit once the device is designed into the medicine. In July 2026 West sold its wearable pump for large doses to AbbVie for about $136M, having judged the returns too thin — so the line is smaller now, and what is left has to grow through that hole.
West Synchrony S1PFS
A complete prefillable syringe West sells as one tested system instead of just the plunger inside someone else's. On sale since January 2026, with no revenue disclosed and no mention on the two calls since.
Competes with EZ-fill ready-to-use syringe systems (Stevanato) · PremiumCoat prefilled-syringe platform (Aptar)
In plain English
Until now West mostly sold one piece of a syringe — the rubber tip on the plunger — to whoever built the rest. Synchrony is the whole thing: barrel, plunger and seal, tested together and handed over with the thick file of test data a drug company needs for its own filing.
The pitch is convenience. A customer can buy one verified package instead of assembling parts from several suppliers and proving the combination works itself. It went on sale in January 2026; management calls the economics very attractive and the journey a long one, and has not put a sales number on it.
High-Value Components (NovaPure, Westar)Washed, coated and camera-checked stoppers and plungers for biologic medicines — the single biggest engine, at 49% of sales in the latest quarter and guided to grow in the high teens this year.Washed, coated and camera-checked stoppers and plungers for biologic medicines — the single biggest engine, at 49% of sales in the latest quarter and guided to grow in the high teens this year.
In plain English
Think of the rubber stopper in a drug vial. The plain version just seals the bottle. This is the same part, washed, coated with a slippery film, checked by cameras and shipped with a paper trail — because a modern biologic medicine reacts with anything less.
Drug companies pay notably more per part for that, and they keep paying: the exact stopper is written into the medicine's regulatory filing, so swapping it means re-doing safety work with the regulator. West says it is on more than nine in ten new biologic and copycat-biologic approvals. The buyers are few — ten customers were just under half of 2025 sales, and one customer West does not name was about a sixth on its own.
Competes with OmniFlex stoppers · NeoFlex plungers (Datwyler) · PremiumCoat coated stoppers and plungers (Aptar)
GLP-1 component and assembly programSeals for weight-loss and diabetes injections, plus the pens West snaps together — management sizes the whole thing near 17% of sales. Whether the new pills add patients or replace shots is the thing to watch.Seals for weight-loss and diabetes injections, plus the pens West snaps together — management sizes the whole thing near 17% of sales. Whether the new pills add patients or replace shots is the thing to watch.
In plain English
The weight-loss and diabetes injections that have become the fastest-growing part of West's mix reach patients as a vial, a cartridge or a pre-filled pen. Every one of those needs a rubber seal West makes, and some of the pens are assembled by West too.
So the same wave pays twice: once for the parts, once for the assembly labour. Management says most of the volume sits with the two biggest makers of these drugs, and declines to name them. Its own read is that the new swallowable versions bring in fresh patients rather than replace injections — if that read is wrong, this is the line that feels it first.
Competes with Coated seals for pens and vials (Datwyler) · Auto-injector pen assembly (Phillips-Medisize) · Device moulding and assembly (SMC Ltd.)
Annex 1 upgrade programEurope's rewritten hygiene rules push drug companies to re-qualify medicines already on sale onto upgraded parts — about two points of 2025 growth. Under 15% of roughly six billion West parts on marketed drugs has converted so far.Europe's rewritten hygiene rules push drug companies to re-qualify medicines already on sale onto upgraded parts — about two points of 2025 growth. Under 15% of roughly six billion West parts on marketed drugs has converted so far.
In plain English
European rules for making injectable medicines were rewritten, and the new version asks manufacturers to prove they keep particles and germs out at every step. One response is to buy parts that arrive already washed, coated and camera-checked.
That turns a rulebook into a sales pipeline. Each switch is its own small project — West has counted hundreds running at once, over seven hundred started in total — and when one lands, a customer who was buying the cheap part starts buying the expensive one instead. No new factory, no new customer: the same parts, at a better price.
Competes with OmniFlex and NeoFlex conversions (Datwyler) · PremiumCoat conversions (Aptar)
Daikyo Seiko allianceWest owns 49% of Daikyo Seiko in Japan and licenses its coating film and clear syringe plastic. The agreements were renewed in July 2026 for ten years, taking renewal worry off the table until 2036.West owns 49% of Daikyo Seiko in Japan and licenses its coating film and clear syringe plastic. The agreements were renewed in July 2026 for ten years, taking renewal worry off the table until 2036.
In plain English
What makes West's premium stopper premium is partly a paper-thin slippery film called FluroTec — and West does not own it. It licenses that film, plus a clear plastic used for syringes and containers, from Daikyo Seiko, a Japanese partner of more than fifty years that West owns just under half of.
The arrangement runs both ways: West sells Daikyo's products everywhere outside Japan, Daikyo sells West's inside Japan, and the stake means a share of Daikyo's economics comes back to West. Its two main rivals coat parts in their own plants. West rents the recipe instead — and has just re-signed the lease for a decade.
Competes with In-house fluoropolymer spray coating (Datwyler) · In-house ETFE film coating (Aptar)
Standard ProductsPlain uncoated stoppers and seals, roughly a fifth of sales and growing 0–1% on purpose. Its job is to be the pool that upgrades come from; the risk is price competition at the cheap end, not lost volume.Plain uncoated stoppers and seals, roughly a fifth of sales and growing 0–1% on purpose. Its job is to be the pool that upgrades come from; the risk is price competition at the cheap end, not lost volume.
In plain English
The unglamorous bottom rung. A plain rubber stopper, moulded and shipped — no coating, no washing service, no camera check, and a price to match. Generic and simple medicines do not need more than that.
Growth here is close to nothing, and West is relaxed about it, because these are exactly the customers it wants to move up a rung. Every conversion takes a dollar out of this line and puts a bigger one into the coated line, so flat is what winning looks like here. What would actually hurt is rivals undercutting on price at the cheap end.
Competes with Uncoated bromobutyl stoppers (Datwyler) · Base bromobutyl formulations (Aptar)
West VantageThe contract arm: West moulds and assembles devices other companies designed, $582.0M in 2025. Management calls the third quarter of 2026 its low point as a glucose-monitor contract exits and the May break-in still echoes.The contract arm: West moulds and assembles devices other companies designed, $582.0M in 2025. Management calls the third quarter of 2026 its low point as a glucose-monitor contract exits and the May break-in still echoes.
In plain English
Other companies bring the blueprint; West runs the factory. Clean-room moulding, welding and automated assembly of things somebody else designed and sells — injector pens, surgical, eye-care and diagnostic items, even consumer products.
Customers pay per part built, so the money follows how full the lines are. Two things emptied them this year: a glucose-monitor programme West decided not to renew is rolling off, and the May 2026 computer break-in that encrypted systems pushed work into later months. New drug-handling work at the expanded Dublin plant, around $20M this year, is meant to fill the space.
Competes with Phillips-Medisize contract assembly (Molex) · Regional moulding and assembly (SMC Ltd.) · Packaging and assembly services (PCI Pharma)
Delivery Devices (SelfDose, Crystal Zenith)West's own injectors and clear-plastic syringe systems, about 14% of sales. The line grew 29% in the latest quarter, flattered by orders pulled forward before the SmartDose handover to AbbVie removed roughly $110M of annual sales.West's own injectors and clear-plastic syringe systems, about 14% of sales. The line grew 29% in the latest quarter, flattered by orders pulled forward before the SmartDose handover to AbbVie removed roughly $110M of annual sales.
In plain English
Beyond the stoppers, West sells finished hardware: a small injector the patient presses themselves, and syringes and containers made from a clear plastic rather than glass, licensed from its Japanese partner.
Drug companies buy these when they want the dose given by the patient rather than by a clinician, and they buy by the unit once the device is designed into the medicine. In July 2026 West sold its wearable pump for large doses to AbbVie for about $136M, having judged the returns too thin — so the line is smaller now, and what is left has to grow through that hole.
Competes with Nexa and Alba syringe systems (Stevanato) · PremiumCoat plungers for prefilled syringes (Aptar)
West Synchrony S1PFSA complete prefillable syringe West sells as one tested system instead of just the plunger inside someone else's. On sale since January 2026, with no revenue disclosed and no mention on the two calls since.A complete prefillable syringe West sells as one tested system instead of just the plunger inside someone else's. On sale since January 2026, with no revenue disclosed and no mention on the two calls since.
In plain English
Until now West mostly sold one piece of a syringe — the rubber tip on the plunger — to whoever built the rest. Synchrony is the whole thing: barrel, plunger and seal, tested together and handed over with the thick file of test data a drug company needs for its own filing.
The pitch is convenience. A customer can buy one verified package instead of assembling parts from several suppliers and proving the combination works itself. It went on sale in January 2026; management calls the economics very attractive and the journey a long one, and has not put a sales number on it.
Competes with EZ-fill ready-to-use syringe systems (Stevanato) · PremiumCoat prefilled-syringe platform (Aptar)
Named in filings, launches and programs
- NovaPureProductThe top coated rung of stoppers and plungers, aimed at biologic medicines and priced accordingly.
- NovaChoiceProductThe non-laminated sibling of NovaPure, and a key part in GLP-1 vials, cartridges and pens.
- Westar RU/RSProductWash grades that tell a customer how clean the components arrive before they are filled.
- FluroTecProductThe thin barrier film that makes a stopper 'coated' — licensed from Daikyo, central to the premium parts.
- Envision verificationServiceAutomated camera inspection sold as a finishing step — one reason customers pay up for the upgraded parts.
- Pharma WashingServiceComponent washing paired with camera inspection for contamination-control plans; interest is spreading outside Europe.
- Flip-Off sealsProductAluminium-and-plastic seals that close the top of a vial — part of the containment range.
- LyoTec stoppersProductStoppers made for freeze-dried drug products, a specialised corner of the vial range.
- Ready PackProductSmall ready-to-use kits of components for customers whose medicine is still in development and ordering tiny quantities.
- Daikyo D Sigma / RUV / RSV stoppersProductDaikyo-branded stopper families that West distributes everywhere outside Japan.
- Crystal ZenithProductDaikyo's clear plastic used for syringes and containers instead of glass; West is the distributor outside Japan.
- Analytical lab servicesServiceLab testing of what might migrate out of a component into the medicine — small, and never raised on calls.
- Drug handling services, DublinService · RampingNew capability at the expanded Dublin plant, about $20M of 2026 sales, filling space the glucose-monitor work vacates.
- Greenfield, Indiana siteService · AnnouncedA manufacturing site announced in January 2026, adding to the contract-assembly network.
NovaPureProduct
The top coated rung of stoppers and plungers, aimed at biologic medicines and priced accordingly.
NovaChoiceProduct
The non-laminated sibling of NovaPure, and a key part in GLP-1 vials, cartridges and pens.
Westar RU/RSProduct
Wash grades that tell a customer how clean the components arrive before they are filled.
FluroTecProduct
The thin barrier film that makes a stopper 'coated' — licensed from Daikyo, central to the premium parts.
Envision verificationService
Automated camera inspection sold as a finishing step — one reason customers pay up for the upgraded parts.
Pharma WashingService
Component washing paired with camera inspection for contamination-control plans; interest is spreading outside Europe.
Flip-Off sealsProduct
Aluminium-and-plastic seals that close the top of a vial — part of the containment range.
LyoTec stoppersProduct
Stoppers made for freeze-dried drug products, a specialised corner of the vial range.
Ready PackProduct
Small ready-to-use kits of components for customers whose medicine is still in development and ordering tiny quantities.
Daikyo D Sigma / RUV / RSV stoppersProduct
Daikyo-branded stopper families that West distributes everywhere outside Japan.
Crystal ZenithProduct
Daikyo's clear plastic used for syringes and containers instead of glass; West is the distributor outside Japan.
Analytical lab servicesService
Lab testing of what might migrate out of a component into the medicine — small, and never raised on calls.
Drug handling services, DublinService · Ramping
New capability at the expanded Dublin plant, about $20M of 2026 sales, filling space the glucose-monitor work vacates.
Greenfield, Indiana siteService · Announced
A manufacturing site announced in January 2026, adding to the contract-assembly network.